### **AGENDA**

# **Third Meeting of the** Secretary's Advisory Committee on Xenotransplantation

November 29-30, 2001 Sheraton Columbia Hotel, Columbia, Maryland

DAY 1- Open Session	
8:30 am	Opening Remarks Dr. Harold Vanderpool (SACX Chair)
8:40 am	Pilot U.S. National Xenotransplantation Database: Update and Demonstration Dr. Eda Bloom (Center for Biologics Evaluation and Research, FDA) – Concept, Objectives, Status Mr. Tom Kruthers (TRW/Stellar Systems, under contract to FDA) – Demonstration
9:40 am	Centralized Xenotransplantation Biological Archive: Update and Discussion Dr. Louisa Chapman (National Center for Infectious Diseases, CDC)
10:15 am	Ethics Training for Committee Members  Dr. Mary Groesch (Executive Director, SACX) – Conflict of Interest  Ms. Holli Beckerman Jaffe (Office of General Counsel, DHHS) – Confidentiality
10:30 am	Break
10:45 am	Xenotransplantation: Meeting Updates, News, and Advances
	Highlights of the VI Congress of the International Xenotransplantation Association Dr. David, K.C. Cooper (Harvard Medical School, and Editor, Xenotransplantation)
	Infection in Xenotransplantation—Recent Data Dr. Jay Fishman (Harvard Medical School)
	Highlights of NHLBI Workshop on Xenotransplantation Dr. Judith Massicot-Fisher (National Heart, Lung and Blood Institute, NIH)

Xenotransplantation Consortium Concept

Dr. Robin Pierson (Vanderbilt University Medical Center)

Highlights of the Recent Vatican Position Statement on Xenotransplantation Dr. Harold Vanderpool (SACX Chair)

12:30 pm Lunch

# 1:45 pm Introduction to SACX Working Groups

SACX WG on the State of the Science in Xenotransplantation

Dr. Jon Allan or Dr. Megan Sykes (SACX Members, WG Co-chairs)

SACX WG on Informed Consent Issues in Xenotransplantation

Ms. Robyn Shapiro or Dr. Harold Vanderpool (SACX Members, WG Co-chairs)

## 2:00 pm Concurrent Working Group Breakout Sessions

4:00 pm Break / Working Groups to develop talking points

4:20 pm Reports of WGs and Plenary Discussion

5:35 pm **Public Comment** 

5:50 pm Adjourn until morning

# DAY 2 – Open Session

#### 8:30 am FDA Overviews and Plenary Discussion

Xenotransplantation IND Overview

Dr. Eda Bloom (Center for Biologics Evaluation and Research, FDA)

An Example of a Xenotransplantation Product Involving Ex Vivo Contact with a Well Characterized Cell Line

Dr. Peter Hudson (FDA Center for Devices and Radiological Health)

Screening for Retrovirus in Xenotransplantation: Overview of Processes and Experiences

Dr. Carolyn Wilson (Center for Biologics Evaluation and Research, FDA)

#### 10:30 am Closing Remarks

Dr. Harold Vanderpool

## DAY 2 – Closed Session

10:30 am FDA Briefing on Xenotransplantation Clinical Research

(FDA Staff)

2:00 pm Meeting Closes